Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.

Zeiser R., Polverelli N., Ram R., Hashmi S. K. , Chakraverty R., Middeke J. M. , ...More

The New England journal of medicine, vol.385, pp.228-238, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 385
  • Publication Date: 2021
  • Doi Number: 10.1056/nejmoa2033122
  • Title of Journal : The New England journal of medicine
  • Page Numbers: pp.228-238


Background Chronic graft-versus-host disease (GVHD), a major complication of allogeneic stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in approximately 50% of patients. Robust data from phase 3 randomized studies evaluating second-line therapy for chronic GVHD are lacking. In retrospective surveys, ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory or -dependent chronic GVHD.